During a seminar in Almedalen on the 5th of July, Opticom presented a report on why the use of innovative drugs differs between comparable countries in Europe. The report was prepared on behalf of LIF, the trade association for the research-based pharmaceutical industry in Sweden. To provide LIF with a deeper understanding of why the use of innovative drugs differs among comparable countries, Opticom conducted interviews with approximately 200 Key Opinion Leaders and representatives for government authorities and other national organisations, in four core therapeutic areas in six European countries: Sweden, Denmark, the Netherlands, Germany, the United Kingdom and France.


For the four selected therapeutic areas, IMS Health provided LIF and Opticom with data how innovative medicines are prescribed in the various countries, which in turn enabled a ranking of countries. These rankings then formed the basis for discussion with the respondents. For the therapeutic areas that the survey focused on – Alzheimer’s, anticoagulants, diabetes, and oncology Sweden landed in positions 10 to 17, when the use of innovative drugs compared to 27 European countries.

The fact that Sweden is relatively low in these international comparisons is something that surprises respondents outside Sweden. The image of Sweden as an innovative country with high welfare is fairly widespread in Europe leads to the expectation that Sweden would be a country that should take more of a leading position.

To access a summary of the results, please choose your language below:
English or Swedish

To access the full report (in Swedish) – click here.

For more information about this report, please contact project manager Marijn van der Sluijs at +46 8 50 30 90 00 or marijn [at] opticom [dot] se.

Email Linkedin Facebook Twitter
Download PDF